Compass Pathways is expected to post a Q2 loss of $0.46 per share on zero revenue, with its current $8.42 share price trading significantly lower than the $35.00 analyst consensus target.
The primary focus for investors is the status of the COMP360 Phase 3 program, specifically the timing for the COMP005 pivotal trial data. Management is also expected to provide updates on its cash runway, which currently extends into late 2027, ensuring liquidity through major clinical milestones. Recent market sentiment has been driven by the anticipation of regulatory filings for psilocybin-based therapies, making this update a critical catalyst for the stock.